DaVita (DVA)
(Delayed Data from NYSE)
$137.72 USD
+1.77 (1.30%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $137.80 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$137.72 USD
+1.77 (1.30%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $137.80 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
CVS Health's Latest Alliances to Fortify Kidney-Care Business
by Zacks Equity Research
With a growing incidence of chronic kidney diseases and end-stage renal failure in the United States, CVS Health's (CVS) new partnerships seem to be strategic.
Time to Focus on DaVita (DVA) for Strong Earnings Growth Potential
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DaVita (DVA).
Why DaVita (DVA) Stock Might be a Great Pick
by Zacks Equity Research
DaVita (DVA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Has DaVita (DVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Top Ranked Growth Stocks to Buy for February 27th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, February 27th
Why DaVita (DVA) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DaVita (DVA).
Why DaVita (DVA) Could Be Positioned for a Surge
by Zacks Equity Research
DaVita (DVA) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics
Top Ranked Growth Stocks to Buy for February 19th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 19th
5 Stocks in Focus on Remarkable Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
Zacks.com featured highlights include: DaVita, Legg Mason, PG&E, Cardinal Health and McKesson
by Zacks Equity Research
Zacks.com featured highlights include: DaVita, Legg Mason, PG&E, Cardinal Health and McKesson
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
DaVita (DVA) gains from solid results in the fourth quarter of 2019.
5 Great GARP Stocks Based on Discounted PEG
by Urmimala Biswas
PEG-based investing can be more rewarding with the addition of a few other relevant parameters.
New Covid-19 Cases Increase, 5 Defensive Stocks to Buy
by Zacks Equity Research
Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.
Top Ranked Momentum Stocks to Buy for February 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 12th
New Strong Buy Stocks for February 12th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
Top Ranked Growth Stocks to Buy for February 12th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 12th
DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss
by Zacks Equity Research
DaVita (DVA) gains from dialysis services in the United States in Q4.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects to have gained from calcimimetics in the fourth quarter.
DaVita HealthCare (DVA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DaVita HealthCare (DVA) Stock Moves -1.39%: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed at $82.03 in the latest trading session, marking a -1.39% move from the prior day.
DaVita HealthCare (DVA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $79.47, moving +0.61% from the previous trading session.
Here's Why You Should Hold on to Becton, Dickinson Stock Now
by Zacks Equity Research
Becton, Dickinson (BDX) expects fiscal 2020 revenue growth to be driven by recent product launches.